MedPath

Y-27632

Generic Name
Y-27632
Drug Type
Small Molecule
Chemical Formula
C14H21N3O
CAS Number
146986-50-7
Unique Ingredient Identifier
0X370ROP6H
Background

Y-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation.

Clinical Trials
Related News

Alcon Acquires Majority Stake in Aurion Biotech to Advance First-Ever Corneal Cell Therapy

• Alcon has acquired a majority interest in Aurion Biotech, positioning itself at the forefront of ophthalmic cell therapy with AURN001, which has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA. • Aurion's innovative cell therapy technology can produce up to 1,000 treatment doses from a single donor, addressing the global shortage of corneal tissue for patients with corneal endothelial disease. • Following successful completion of Phase 1/2 trials with 97 subjects, Aurion plans to advance AURN001 into Phase 3 clinical development in the second half of 2025, with full support from Alcon's global resources.

Aurion Biotech's AURN001 Shows Promise in Phase 1/2 Trial for Corneal Edema

• Aurion Biotech's AURN001, an allogeneic cell therapy, demonstrated statistically significant improvement in visual acuity in patients with corneal edema in a Phase 1/2 trial. • The high-dose AURN001 arm showed that 50% of patients achieved a ≥15-letter improvement in best-corrected visual acuity (BCVA) at 6 months, compared to 14.3% in the Y-27632-only arm. • Key secondary endpoints, including change in BCVA and central corneal thickness, also showed statistically significant improvements in the high-dose AURN001 arm. • AURN001 combines neltependocel (allogeneic human corneal endothelial cells) and Y-27632 (a rho kinase inhibitor) and is intended as a one-time anterior chamber injection.

Error parsing response

Error occurred while parsing the model response.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy